Novartis India Ltd.

NOVARTIND

₹823.5

-2.58% (-21.8)

Market Cap

₹2,087 Cr.

P/E

24.19

About

Novartis India Limited is a pharmaceutical company with operations in Pharmaceuticals, Generics, over the counter (OTC) products, and Animal Health. The company provides prescription medicines through… Read more

Novartis India Limited is a pharmaceutical company with operations in Pharmaceuticals, Generic… Read more

Low

745

52W Range

High

1248

Timeline

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statementNew

Edit rows

Forensics

9 Yes

Positive for this company

1 Neutral

Neutral for this company

7 No

Negative for this company

0 No Data

Insufficient data to analyse

Accounting & Shareholding

Depreciation Effect

Depreciation accounting is not leading to increase in profits
Pledge

Promoters have not pledged a significant portion of their holding
Revenue Recognition

Company is converting accounting profit to cash
Promoter Holding

Promoter has not sold any shares in the last 90 days
Retail Holding

Retail has been buying the stock which is usually a sign of exuberance
Contingent Liabilities

Company has significant contigent liabilities which can be risky
Other Income

Other income component is making ratios of the company look optically better

Price & Performance

Capex vs ROCE

Roce of the company has increased over the last three years
ROE

Net profit margin is responsible for roe increase over last 10 years
Share price

Share price has increased over last 10 years due to earnings
Working Capital

Working capital of the company seems to be under control
Current vs Historic Valuation

Company is trading at a discount to 3yr historic valuations
Debt

Company should not have issues servicing its debt
Sales Growth

Sales of the company has grown at a slow pace
Margin Stability

Margins of the company are volatile
ROCE Strength

Roce of the company is not consistently strong
Balance Sheet Strength

Balance sheet of the company is moderately strong, but it might have issues paying it suppliers

Market Share

1.80 %

(as of Jul 22)

Historic

Anti - Diabetes - Market Share

0.06 %

(as of Jul 22)

Historic

Anti-Infectives - Market Share

0.09 %

(as of Nov 21)

Historic

Antineo Plastic - Market Share

0.14 %

(as of May 19)

Historic

Blood Related - Market Share

0.72 %

(as of Jul 22)

Historic

Cardiovascular - Market Share

0.03 %

(as of Nov 21)

Historic

Dermatology - Market Share

0.01 %

(as of Aug 18)

Historic

Endocrinology - Market Share

0 %

(as of Jul 22)

Historic

Gastro-Intestinal - Market Share

0.85 %

(as of Nov 21)

Historic

Gynecology - Market Share

0.51 %

(as of Nov 21)

Historic

Neurological - Market Share

6.46 %

(as of Nov 21)

Historic

Ophthalmology - Market Share

2.40 %

(as of Nov 21)

Historic

Pain - Market Share

0.55 %

(as of Jul 22)

Historic

Pharmaceutical Sector - Market Share

0.17 %

(as of Nov 21)

Historic

Respiratory - Market Share

0.43 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operational Metrics

Domestic Sales Growth - YoY (%)
Source

Peer Comparison

Brands

Voveran

Corporate Actions

Consolidated

DATE

DETAILS

Show Less

Suppliers

Bharat Dynamics Ltd.
Piramal Enterprises Ltd.
Navin Fluorine International Ltd.
Neuland Laboratories Ltd.
Aarti Industries Ltd.
EPL Ltd.
Morepen Laboratories Ltd.
Gulshan Polyols Ltd.
Allcargo Gati Ltd.
Kilitch Drugs (India) Ltd.
Hindusthan National Glass & Industries Ltd.
Take Solutions Ltd.
Vivimed Labs Ltd.

Showing 5 of 13

FAQs on Novartis India Ltd. Business

What does Novartis do?

Novartis India Limited operates in pharmaceuticals, generics, over the counter (OTC), and animal health segments. It provides prescription medicines, retail generic products, and products for cattle and poultry markets.

Who are the competitors of Novartis?

Novartis major competitors are Indoco Remedies, Beta Drugs, Syncom Formulations, Zota Health Care, Jagsonpal Pharma, Bliss GVS Pharma, Lincoln Pharma.
Market Cap of Novartis is ₹2,087 Crs.
While the median market cap of its peers are ₹1,653 Crs.

Is Novartis financially stable compared to its competitors?

Novartis seems to be less financially stable compared to its competitors.
Altman Z score of Novartis is 2.2 and is ranked 8 out of its 8 competitors.

View FAQ's On Shareprice

Global Leaders

Companies with a dominant global position in a product. Might be a sign of very strong moat.

Run Query

Reasonably Valued Domestic Healthcare Companies

Healthcare companies trading at a decent valuation

Run Query

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release
Investor Presentation													Dec
Conference Call
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Pharmaceutical Sector

How The Pharma Industry Works - PPFAS

Deep Dive into Pharma Sector - Omkara Capital

Pharma Compliance In-Depth - Amit Rajan

Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar

Nutraceuticals- Industry Overview - Value Educator

Generic Opportunity for Indian Pharma Companies - Anish Moonka

Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Novartis India Ltd.